Jon Hamilton | Texas Public Radio

Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Researchers are beginning to understand why certain brain cancers are so hard to stop.

Three studies published Wednesday in the journal Nature found that these deadly tumors integrate themselves into the brain's electrical network and then hijack signals from healthy nerve cells to fuel their own growth.

The depression drug esketamine, marketed as Spravato, appears to offer quick relief to people who are actively considering suicide.

Esketamine, a chemical cousin of the anesthetic and party drug ketamine, reduced depression symptoms within hours in two large studies of suicidal patients, the drug's maker announced Monday.

By the time a fetus is 6 months old, it is producing electrical signals recognizable as brain waves.

And clusters of lab-grown human brain cells known as organoids seem to follow a similar schedule, researchers reported Thursday in the journal Cell Stem Cell.

In mice, scientists have used a variety of drugs to treat brain disorders including murine versions of Alzheimer's disease, depression and schizophrenia. But in people, these same treatments usually fail.

And now researchers are beginning to understand why.

A detailed comparison of the cell types in mouse and human brain tissue found subtle but important differences that could affect the response to many drugs, a team reports Wednesday in the journal Nature.

A close look at the brains of 40 U.S. Embassy workers in Cuba who developed mysterious symptoms has found no evidence of injury. The State Department has said the employees were hurt by some sort of attack.

Researchers are prescribing exercise as if it were a drug in a study that aims to see if it can prevent Alzheimer's disease.

"We are testing if exercise is medicine for people with a mild memory problem," says Laura Baker, principal investigator of the nationwide EXERT study and associate director of the Alzheimer's Disease Research Center at Wake Forest School of Medicine.

In a waiting room at the Banner Alzheimer's Institute in Phoenix, a 74-year-old woman named Rubie is about to find out whether she has a gene that puts her at risk for Alzheimer's.

"I'm a little bit apprehensive about it, and I hope I don't have it," she says. "But if I do, I want to be able to plan for my future."

The gene is called APOE E4, and it's the most powerful known genetic risk factor for Alzheimer's after age 65.

Alzheimer's disease begins altering the brain long before it affects memory and thinking.

So scientists are developing a range of tests to detect these changes in the brain, which include an increase in toxic proteins, inflammation and damage to the connections between brain cells.

Spinal surgery made it possible for Liv Cannon to plant her first vegetable garden.

"It's a lot of bending over and lifting the wheelbarrow and putting stakes in the ground," the 26-year-old says as she surveys the tomatillos, cherry tomatoes and eggplants growing in raised beds behind her house in Austin, Texas. "And none of that I could ever do before."

For the first 24 years of her life, Cannon's activities were limited by chronic pain and muscle weakness.

What sounds like music to us may just be noise to a macaque monkey.

That's because a monkey's brain appears to lack critical circuits that are highly sensitive to a sound's pitch, a team reported Monday in the journal Nature Neuroscience.

The finding suggests that humans may have developed brain areas that are sensitive to pitch and tone in order to process the sounds associated with speech and music.

Pages